- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient Communities: Mandi Bishop Interviews Christopher Snider
In the latest Managed Care Cast, Mandi Bishop, MA, CEO of Aloha Health, interviews Christopher A. Snider, a patient community advocate for Symplur, creator of patient community site My Disease Secret, host of the Just Talking podcast, and social media strategist for Smart Patients.
In the latest Managed Care Cast, Mandi Bishop, MA, CEO of Aloha Health, interviews Christopher A. Snider, a patient community advocate for Symplur, creator of patient community site My Disease Secret, host of the Just Talking podcast, and social media strategist for Smart Patients.
They discuss Snider’s own diabetes diagnosis—he was diagnosed with type 1 diabetes in 2002—and his journey to patient advocate, finding a patient community on social media, what Symplur is doing with Twitter data it captures from disease communities, and more.
“My perspective with Symplur is that there is a lot of data that the patient community could potentially use to improve itself,” he said. “My initial work with them has been to try to figure out how to bring access to this mountain of data … that a lot of people don’t necessarily know exist … try to bring access to the patient community.”
You can follow Christopher on Twitter @iam_spartacus or visit his site at www.christopherasnider.com.
Listen below or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Care Quality Metrics in Medicare During COVID-19 Pandemic
August 12th 2025Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some in-person screenings.
Read More
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
